Switzerland's Roivant Q1 loss widens
ROIV•Cost drivers
- R&D spending - Higher research and development expenses were driven by increased program-specific costs for the anti-FcRn franchise and mosliciguat.
- Personnel costs - Increased personnel expenses, including employee bonuses tied to the Moderna settlement, contributed to higher R&D and G&A costs.
Key financial results
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q1 Revenue | $1.44 mln | ||
| Q1 Adjusted Net Loss | Miss | $290.61 mln | $192.26 mln (4 Analysts) |
| Q1 Net Loss | $290.61 mln | ||
| Q1 Income From Operations | Miss | -$365.99 mln | -$306.78 mln (7 Analysts) |
| Q1 Pretax Loss | Miss | $294.56 mln | $243.70 mln (6 Analysts) |
| Q1 Loss Per Basic Share | $0.26 | ||
| Q1 Operating Expenses | $367.83 mln |
Outlook and analyst coverage
Roivant expects to launch brepocitinib in dermatomyositis by the end of September 2026.
The company expects topline data from Phase 3 NIU and mosliciguat PH-ILD studies in H2 2026.
Roivant says its cash position supports runway into profitability.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
